A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Conditions: Metastatic Breast Cancer Interventions: Drug: Lenvatinib; Drug: Pembrolizuma; Drug: Fulvestrant Sponsors: Memorial Sloan Kettering Cancer Center; Merck Sharp& Dohme LLC Not yet recruiting

https://clinicaltrials.gov/study/NCT06110793

Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials